-+ 0.00%
-+ 0.00%
-+ 0.00%

COMPASS Pathways (CMPS), What Is Behind The Fresh Attention?

Simply Wall St·11/19/2026 07:17:45
Listen to the news

COMPASS Pathways (NasdaqGS:CMPS) has reached a key milestone by completing a New Drug Application to the U.S. FDA for COMP360 psilocybin in treatment-resistant depression, supported by Phase 3 and Phase 2b data.

That regulatory milestone lands after a choppy stretch for COMPASS Pathways, with the 30-day share price return down 26.91% and the 90-day move down 41.24%, even as the year to date share price return is 23.97% and the 1-year total shareholder return is 54.67%. Taken together, this mix suggests long term holders have been rewarded while recent momentum has cooled.

Look beyond COMPASS Pathways and compare its regulatory progress with a curated group of biotech and healthcare prospects in the 37 healthcare AI stocks.

COMPASS Pathways now trades sharply below analyst targets after a steep pullback, even as its NDA clears a major hurdle. Is that discount a safety margin, or a warning sign as investors reassess the risk?

Most Popular Narrative: 67% Undervalued

At a last close of $8.12 versus a fair value of $24.47 from the analyst consensus Narrative on Simply Wall St, COMPASS Pathways is framed as heavily discounted, with that view built on detailed assumptions about trials, approvals and long term earnings power.

COMPASS Pathways currently has no revenue. Analysts are forecasting revenue to reach $284.9 million by July 2029.

If COMPASS Pathways's profit margin were to converge on the industry average, you could expect earnings to reach $53.9 million (and earnings per share of $0.33) by about July 2029, up from $192.4 million of losses today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $280.4 million in earnings, and the most bearish expecting $452.3 million of losses.

See why 16 investors see COMPASS Pathways as 67% undervalued.

The discount rate used in that framework is 7.63%, and the 67% discount to the $24.47 fair value reflects those specific revenue, margin and earnings assumptions rather than any guarantee about where the CMPS share price will trade.

Result: Fair Value of $24.47 (UNDERVALUED)

Still, the COMPASS Pathways story leans heavily on successful Phase 3 outcomes and timely FDA decisions. At the same time, higher spending and any funding gap could quickly challenge that bullish narrative.

Find out about the key risks to this COMPASS Pathways narrative.

Another View: What COMPASS Pathways’ Valuation Signals Are Saying

The earlier fair value of $24.47 leans on long range earnings forecasts and a rich implied future P/E. A different lens looks at today’s pricing versus future cash flows. Our DCF model currently points to a future cash flow value of $148.90, which frames COMPASS Pathways as heavily undervalued. Is that a genuine margin of safety, or just a sign that the inputs are highly optimistic?

Look into how the SWS DCF model arrives at its fair value.

CMPS Discounted Cash Flow as at Nov 2026
CMPS Discounted Cash Flow as at Nov 2026

Next Steps

Mixed signals on COMPASS Pathways so far, right. Act while the information is fresh, review both sides of the story and weigh the 2 key rewards and 4 important warning signs.

Looking for more COMPASS Pathways style investment ideas?

Do not stop with COMPASS Pathways. Use this momentum to look for other opportunities that fit your goals before the best ideas move without you.